Cyclo Therapeutics, Inc.

NasdaqCM:CYTH Stock Report

Market Cap: US$37.0m

Cyclo Therapeutics Management

Management criteria checks 4/4

Cyclo Therapeutics' CEO is N. Fine, appointed in Sep 2015, has a tenure of 8.58 years. total yearly compensation is $672.89K, comprised of 80.4% salary and 19.6% bonuses, including company stock and options. directly owns 2.59% of the company’s shares, worth $959.51K. The average tenure of the management team and the board of directors is 6.7 years and 9.4 years respectively.

Key information

N. Fine

Chief executive officer

US$672.9k

Total compensation

CEO salary percentage80.4%
CEO tenure8.6yrs
CEO ownership2.6%
Management average tenure6.7yrs
Board average tenure9.4yrs

Recent management updates

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jan 20
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov 16

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Sep 28
Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Cyclo therapeutics to join Russell 2000 Index

Jun 14

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jun 12
We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease

Jan 05

How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Dec 12
How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

CEO Compensation Analysis

How has N. Fine's remuneration changed compared to Cyclo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$673kUS$541k

-US$20m

Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$541k

-US$15m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$508k

-US$14m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$489kUS$400k

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$490kUS$400k

-US$8m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$467kUS$400k

-US$4m

Sep 30 2018n/an/a

-US$4m

Jun 30 2018n/an/a

-US$4m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$441kUS$400k

-US$4m

Compensation vs Market: N.'s total compensation ($USD672.89K) is about average for companies of similar size in the US market ($USD668.06K).

Compensation vs Earnings: N.'s compensation has been consistent with company performance over the past year.

CEO

N. Fine (66 yo)

8.6yrs

Tenure

US$672,888

Compensation

Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...

Leadership Team

NamePositionTenureCompensationOwnership
N. Fine
CEO & Director8.6yrsUS$672.89k2.59%
$ 959.5k
C. Strattan
Founder & Directorno dataUS$33.00k1.65%
$ 609.6k
Joshua Fine
CFO & Secretary10.3yrsUS$463.98k0.059%
$ 21.8k
Michael Lisjak
Global Head of Regulatory Affairs & Senior VP of Business Development4.8yrsUS$473.21k0.043%
$ 16.0k
Jeffrey Tate
COO, Chief Quality Officer & Director8.6yrsUS$255.14k0.32%
$ 118.7k
Lori McKenna
Global Head of Patient Advocacy2.9yrsno datano data
Karen Mullen
Interim Chief Medical Officer1.3yrsno datano data

6.7yrs

Average Tenure

65yo

Average Age

Experienced Management: CYTH's management team is seasoned and experienced (6.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
N. Fine
CEO & Director10.2yrsUS$672.89k2.59%
$ 959.5k
C. Strattan
Founder & Director34.3yrsUS$33.00k1.65%
$ 609.6k
Jeffrey Tate
COO, Chief Quality Officer & Director13.7yrsUS$255.14k0.32%
$ 118.7k
William Shanahan
Independent Director7.8yrsUS$40.13k0.41%
$ 152.1k
Markus Sieger
Independent Chairman10.2yrsUS$66.38k1.08%
$ 400.8k
Rita Colwell
Co-Chair of Scientific Advisory Boardno datano datano data
Sharon Hrynkow
Co-Chairman of Scientific Advisory Board9.4yrsUS$600.09kno data
F. Ostronic
Independent Vice Chairman10yrsUS$41.25k1.18%
$ 436.1k
Caroline Hastings
Member of Scientific Advisory Board9.1yrsno datano data
Benny Liu
Member of Scientific Advisory Board8.9yrsno datano data
Gerald F. Cox
Member of Scientific Advisory Board2.6yrsno datano data
Randall Toig
Independent Director6.1yrsUS$35.63k0.37%
$ 135.3k

9.4yrs

Average Tenure

66yo

Average Age

Experienced Board: CYTH's board of directors are considered experienced (9.4 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.